Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Testing Status of AZT/Drug Combinations Transplacental Carcinogenesis Study M020005

 

CASRN: AIDSTHERAPEU

Synonyms/Common Names

  • AZT/3TC/NFV/NVP/EFV

Known Uses

Drugs used in the treatment of HIV - AIDS therapeutics

Short-Term Toxicity

  • 28 days (In Utero)  (C20311)  Completed 
    • Mice: B6C3F1/NCTR BR (C57BL/6N x C3H/HEN MTV-)

Long-Term Carcinogenicity

  • 2 years (In Utero)  (C20311)  Completed 
    • TR-569 (NIH Number: 11-5911)
      Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), Nevirapine (NVP), and Nelfinavir Mesylate (NFV) (CASRNs 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (Transplacental Exposure Studies)
    • Mice: B6C3F1/NCTR BR (C57BL/6N x C3H/HEN MTV-)
    • Dose: AZT: 80 (low), 160 (mid), or 240 (high) mg AZT/kg body weight; AZT +3TC: 80/40 (low), 160/80 (mid), or 240/120 (high) mg AZT/3TC/kg body weight; AZT+ 3TC +NVP: 80/40/56 (low), 160/80/112 (mid), or 240/120/168 (high) mg AZT/3TC/NVP/kg body weight; AZT + 3TC + NFV: 80/40/336 (low), 160/80/672 (mid), or 240/120/1, 008 (high) mg AZT/3TC/NFV/kg body weight.